Nutriband Inc. Advances Toward FDA Approval for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband Inc. has secured a Type C Meeting with the FDA for its AVERSA(TM) Fentanyl patch, a significant step towards introducing the world's first abuse-deterrent opioid patch to the market.
Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing prescription transdermal pharmaceutical products, has reached a pivotal milestone in its quest to combat the opioid crisis. The U.S. Food and Drug Administration (FDA) has scheduled a Type C Meeting for September 18, 2025, to review the Chemistry, Manufacturing, and Controls (CMC) plans for its innovative product, AVERSA(TM) Fentanyl. This development marks a critical step in the regulatory process, bringing the company closer to offering a solution designed to mitigate the risks associated with fentanyl patches.
The AVERSA(TM) Fentanyl patch, developed in collaboration with Kindeva, represents a groundbreaking approach to opioid delivery. By integrating Nutriband's proprietary abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, the product aims to prevent abuse, diversion, misuse, and accidental exposure, while ensuring that patients in need retain access to this essential medication. With patents protecting the technology in 46 countries, AVERSA(TM) Fentanyl is poised to set a new standard in opioid therapy.
The potential market impact of AVERSA(TM) Fentanyl is significant, with peak annual U.S. sales projected between $80 million and $200 million. Beyond its immediate financial implications, the successful development and approval of this patch could herald a new era in the fight against opioid abuse, offering a model for future abuse-deterrent medications. For more information on Nutriband Inc. and its innovative technologies, visit https://www.nutriband.com.
This announcement underscores the importance of innovation in addressing public health challenges. As the opioid epidemic continues to devastate communities across the globe, solutions like AVERSA(TM) Fentanyl offer hope for reducing the harm associated with these powerful medications. The upcoming FDA meeting is not just a procedural step; it represents a potential turning point in the way opioids are prescribed and used, with implications for patients, healthcare providers, and society at large.